This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Drostanolone propionate, or drostanolone 17β-propionate, is a synthetic androstane steroid and a derivative of DHT. It is the C17β propionate (propanoate) ester of drostanolone, which itself is 2α-methyl-4,5α-dihydrotestosterone (2α-methyl-DHT) or 2α-methyl-5α-androstan-17β-ol-3-one.
In international law, "everyone" has the right to fair pay, to equal treatment, to join a union, to take collective action, and to social security including job security. However the scope of who has rights under the Fair Work Act 2009, including for award wages, paid holidays, collective bargaining, and job security, depends on the test for who is an employee, as opposed to an "independent contractor". Historically, this distinction was based on the view that employees have systematically unequal bargaining power, and therefore needed positive legal rights that would otherwise be lost in take-it-or-leave-it contracts that the employer imposed. The common law distinguished employees from the self-employed (who are responsible for their own rights, or fell back on the state), based on the employer's exercise of control, for instance over place or conditions of work. Courts asked whether workers were carrying "on a trade or business of his own", and viewed a contract's terms as obscuring reality, not revealing it. As a court said in 1988: "The parties cannot create something which has every feature of a rooster, but call it a duck and insist that everyone else recognise it as a duck". As well as control, courts looked at multiple factors including whether work was done personally, whether the worker works for others, the method of pay, ownership of equipment, trade marks, good will, and who got profits or bore losses.
Gordon R. Ward, writing in the correspondence columns of the British Medical Journal, proposed the use of blood plasma as a substitute for whole blood and for transfusion purposes as early as 1918. At the onset of World War II, liquid plasma was used in Britain. A large project, known as "Blood for Britain", began in August 1940 to collect blood in New York City hospitals for the export of plasma to Britain. Following heavy casualties in the Battle of Dunkirk, the Blood Transfusion Association in New York City originated the campaign that was enlarged to the whole US by the Red Cross, and was called the National Blood Programme. At the time, American physician Edwin Cohn pioneered the process of blood fractionation. He worked out the techniques for isolating the serum albumin fraction of blood plasma, which is essential for maintaining the osmotic pressure in the blood vessels, preventing their collapse. A freeze-dried plasma package was developed by the Surgeons General of the Army and Navy, working with the National Research Council, which reduced breakage and made transportation, packaging, and storage much simpler.
On 3 September, Robert Fripp said that his differences with Adrian Belew had been resolved and that, while there were "no current plans for [him] to come out with the current formation," he could potentially be invited back to the band in the future. Belew subsequently confirmed this. On 14 October 2017, King Crimson released another contemporary live album, Live in Chicago, recorded on tour in June of the same year. As had been the case with its two predecessors, it included new material (in this case "Bellscape & Orchestral Werning", "The Errors" and "Interlude"); it also documented the return to the live set of material from Lizard (in the form of "Cirkus", which the band had begun adding to their sets in 2016, and the second half of the title suite), as well as new arrangements of some Belew-era songs. On 13 October 2017, it was announced that Rieflin would be unable to join the Three Over Five Formation on the 2017 Autumn tour in the U.S. He was temporarily replaced by Seattle-based Crafty Guitarist Chris Gibson. During 2018, King Crimson performed the extensive 33-date Uncertain Times tour through the UK and Europe between 13 June and 16 November. Although the band continued to avoid studio recording, April 2018 saw the full release of another live album, Live in Vienna, presenting the complete concert in Vienna on 1 December 2016.
Protein Ser/Thr phosphatases were originally classified using biochemical assays as either, type 1 (PP1) or type 2 (PP2), and were further subdivided based on metal-ion requirement (PP2A, no metal ion; PP2B, Ca2+ stimulated; PP2C, Mg2+ dependent) (Moorhead et al., 2007). The protein Ser/Thr phosphatases PP1, PP2A and PP2B of the PPP family, together with PP2C of the PPM family, account for the majority of Ser/Thr PP activity in vivo (Barford et al., 1998). In the brain, they are present in different subcellular compartments in neuronal and glial cells, and contribute to different neuronal functions.
Sources: en.wikipedia.org
Follow-up longitudinal studies of women with prosthetic breasts indicated no causal relation between the presence of a breast prosthesis and the occurrence of either a systemic disease or an autoimmune disease. European and North American studies reported that women who had undergone an augmentation mammoplasty tended to be healthier than the general population; that plastic surgery patients had a lower standardized mortality ratio than did other types of surgery patient; and that women with prosthetic breasts faced a greater rate of incidence for lung cancer than did other types of plastic-surgery patient. Moreover, because only the study Long-term Cancer Risk among Swedish Women with Cosmetic Breast Implants: an Update of a Nationwide Study (2006) controlled for tobacco smoking, the data were insufficient to establish verifiable statistical differences between smokers and non-smokers and the greater incidence of death by lung cancer for women with prosthetic breasts. The long-term study of 25,000 women, Mortality among Canadian Women with Cosmetic Breast Implants (2006), reported that breast prostheses do not directly increase mortality in women. The study Silicone-gel Breast Implant Rupture, Extracapsular Silicone, and Health Status in a Population of Women (2001) reported an increased rate of incidence of fibromyalgia among women who had suffered a capsular contracture that leaked silicone-gel, than among women whose prosthetic breasts had neither ruptured nor leaked.
== Stem cell treatments == Haematopoietic stem cells (HSC) are cells in the bone marrow that can develop into all types of blood cells, including red blood cells, white blood cells, and platelets. There are two possible ways to treat sickle cell disease and some other hemoglobinopathies by targeting HSCs. Since 1991, a small number of patients have received bone marrow transplants from healthy matched donors. This procedure is high-risk. More recently, it has become possible to use CRISPR gene editing technology to modify the patient's own HSCs in a way that reduces or eliminates the production of sickle haemoglobin HbS and replaces it with a non-sickling form of haemoglobin. All stem cell treatments must involve myeloablation of the patients' bone marrow to remove HSCs containing the faulty gene. This requires high doses of chemotherapy agents with side effects such as sickness and fatigue. A long hospital stay is necessary after infusion of the replacement HSCs, while the cells take up residence in the bone marrow and make red blood cells with the stable form of haemoglobin.
Kaplan (1922), acting chancellor of University of Maryland, Baltimore County and president of Baltimore Hebrew University Frederick Burkhardt (1933), president emeritus of the American Council of Learned Societies and third president of Bennington College James S. Coles (1936), ninth president of Bowdoin College William C. Fels (1937), fourth president of Bennington College George James (1937), commissioner of Health of the City of New York, dean of the Mount Sinai School of Medicine, president of Mount Sinai Health System James C. Fletcher (1940), president of the University of Utah and administrator of the National Aeronautics and Space Administration Herbert A. Deane (1942), political scientist, vice provost of Columbia University Martin Meyerson (1942), president of the University of Pennsylvania Henry S. Coleman (1946), acting dean of Columbia College, Columbia University during the Columbia University protests of 1968 Steven Marcus (1948), George Delacorte Professor in the Humanities and dean of Columbia College Carl Hovde (1950), professor of English and dean of Columbia College following the Columbia University protests of 1968 Rudolph H. Weingartner (1950), former provost of the University of Pittsburgh, former dean of the College of Arts and Sciences at Northwestern University Ralph Lowenstein (1951), dean of the University of Florida College of Journalism and Communications Michael I. Sovern (1951), president of Columbia University Richard N.
=== Fluorescence === Progress in molecular biology over the last six decades has produced powerful tools that facilitate the dissection of biochemical and genetic signals; yet, they tend to not be well-suited for bioelectric studies in vivo. Prior work relied extensively on current applied directly by electrodes, reinvigorated by significant recent advances in materials science and extracellular current measurements, facilitated by sophisticated self-referencing electrode systems. While electrode applications for manipulating neuraly-controlled body processes have recently attracted much attention, there are other opportunities for controlling somatic processes, as most cell types are electrically active and respond to ionic signals from themselves and their neighbors. In the early part of the 21st century, a number of new molecular techniques were developed that allowed bioelectric pathways to be investigated with a high degree of mechanistic resolution, and to be linked to canonical molecular cascades. These include:
=== Adhesive consolidation === Fragile and brittle fabrics, or those that would be damaged by needle and thread repairs, can be consolidated using adhesive techniques. Consolidation is less common than stitching methods. Lack of extensive research into the long-term stability of synthetic adhesives and their compatibility with natural fibers has contributed to polarized debate over the appropriateness of adhesive consolidation. The complexity of treatments and limited expertise with theory and practice and often prevent conservators from choosing this option. Among the variables to be considered are the concentration and number of coats of adhesive, substrates, and application and reactivation methods. Evaluation of past consolidation failures and successes, and interdisciplinary collaboration among professionals, have led to a more refined and informed practice. Despite the challenges, skillfully applied adhesive supports are a viable alternative to stitching.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.